Overcoming Challenges with Transpara
In addition to extensive clinical research published in peer reviewed journals, we are always excited to share insights gathered along the path of rigorous scientific study and clinical practice.
Nico Karssemeijer, Chief Science Officer and Co-Founder of ScreenPoint Medical, joins Impact AI podcast to discuss how his team is revolutionizing breast cancer screening through cutting-edge AI.
Only randomized controlled trial of its kind highlights impact of Transpara Breast AI
Deal brings enhanced capabilities for ScreenPoint’s industry-leading Transpara Breast AI.
© 2025, ScreenPoint Medical BV. All rights reserved. Transpara® is a registered trademark of ScreenPoint Medical BV. Reproduction of any material contained herein in any format or media without express written permission of ScreenPoint Medical BV is prohibited. *Disclaimer: Transpara is CE marked and FDA cleared for 2D and 3D mammography. CE (0344) certified. FDA 510(k) K241831 and K232096. Not all features are available in all countries. Please check with local representatives.
Lake Medical Imaging Case Study
Download the study to see how Transpara reduces radiologist workload and improves diagnostic confidence.
